Loading...

Biotech company raises $360 million for cancer-detecting blood test

Loading...
Biotech company raises $360 million for cancer-detecting blood test - Apa khabar sahabat TIMES NEW MALAYSIA, Dalam artikel yang anda baca kali ini dengan tajuk Biotech company raises $360 million for cancer-detecting blood test, kami telah menyediakan dengan baik untuk artikel ini anda membaca dan memuat turun maklumat di dalamnya. mudah-mudahan mengisi jawatan Artikel BOLASEPAK, Artikel NEWS, Artikel PERNIAGAAN, kita menulis ini, anda boleh memahami. Nah, selamat membaca.

Tajuk : Biotech company raises $360 million for cancer-detecting blood test
link : Biotech company raises $360 million for cancer-detecting blood test

lihat juga


Biotech company raises $360 million for cancer-detecting blood test


A California-based biotech company raised $360 million to fund a new early warning system that could detect cancer with a simple blood test. Guardant Health raised the funding for Guardant360, a blood test that measures genetic biomarkers for tumors, or a “liquid biopsy.” The blood would detect “circulating tumor DNA (ctDNA),” tiny bits of DNA a tumor releases in the blood stream at it grows. According to the National Human Genome Research Institute, ctDNA tracking is a less-invasive and safer alternative to a tumor biopsy. The ctDNA can often be used to detect cancer as it’s growing, increasing the chances it’s caught early.…

This story continues at The Next Web

✍ Sumber Pautan : ☕ The Next Web

Kredit kepada pemilik laman asal dan sekira berminat untuk meneruskan bacaan sila klik link atau copy paste ke web server : http://ift.tt/2pGRXtK

(✿◠‿◠)✌ Mukah Pages : Pautan Viral Media Sensasi Tanpa Henti. Memuat-naik beraneka jenis artikel menarik setiap detik tanpa henti dari pelbagai sumber. Selamat membaca dan jangan lupa untuk 👍 Like & 💕 Share di media sosial anda!

Loading...

A California-based biotech company raised $360 million to fund a new early warning system that could detect cancer with a simple blood test. Guardant Health raised the funding for Guardant360, a blood test that measures genetic biomarkers for tumors, or a “liquid biopsy.” The blood would detect “circulating tumor DNA (ctDNA),” tiny bits of DNA a tumor releases in the blood stream at it grows. According to the National Human Genome Research Institute, ctDNA tracking is a less-invasive and safer alternative to a tumor biopsy. The ctDNA can often be used to detect cancer as it’s growing, increasing the chances it’s caught early.…

This story continues at The Next Web

✍ Sumber Pautan : ☕ The Next Web

Kredit kepada pemilik laman asal dan sekira berminat untuk meneruskan bacaan sila klik link atau copy paste ke web server : http://ift.tt/2pGRXtK

(✿◠‿◠)✌ Mukah Pages : Pautan Viral Media Sensasi Tanpa Henti. Memuat-naik beraneka jenis artikel menarik setiap detik tanpa henti dari pelbagai sumber. Selamat membaca dan jangan lupa untuk 👍 Like & 💕 Share di media sosial anda!



dengan itu Perkara Biotech company raises $360 million for cancer-detecting blood test

yang semua artikel Biotech company raises $360 million for cancer-detecting blood test Kali ini, diharapkan dapat memberi manfaat kepada anda semua. Okay, jumpa di lain post artikel.

Kini anda membaca artikel Biotech company raises $360 million for cancer-detecting blood test dengan alamat pautan https://timesnewmalaysia.blogspot.com/2017/05/biotech-company-raises-360-million-for.html

Subscribe to receive free email updates:

0 Response to "Biotech company raises $360 million for cancer-detecting blood test"

Catat Ulasan

Loading...